The Ticker

JP Morgan reaches $4B deal with feds

JPMorgan Chase & Co. has reached a tentative $4 billion deal with the U.S. Federal Housing Finance Agency to settle claims that the bank misled government-sponsored mortgage agencies about the quality of mortgages it sold to them during the housing boom, the Wall Street Journal reported online yesterday.

The deal is for less than the $6 billion the agency initially sought, the Journal said, citing people close to the discussions.

Ariad in trouble after failed study

Cambridge-based Ariad Pharmaceuticals Inc. is working on a new financial plan after increased risks of blood clots stopped a study aimed at expanding use of its only approved drug. The shares sank.

The study, called Epic, was testing Ariad's Iclusig against Novartis AG Gleevec in newly diagnosed chronic myeloid leukemia. Iclusig is still on the market and the company is working with regulators on changing the drug's labeling to reflect the safety findings, Ariad said yesterday in a statement.

"It's the end of Ariad as we know it," Mike King, an analyst with JMP Securities, said yesterday. The risks will relegate Iclusig to "break glass in case of emergency" use only, said King, who predicted the company may fire workers and halt plans to expand its headquarters.

Ariad will work in the next few weeks to put a new financial and operating plan in place, Chief Executive Officer Harvey Berger told analysts and investors on a conference call. It's premature to discuss the potential for a partnership or sale of the company, he said in response to a question.

"We are working as a team on a substantially revised financial plan that will extend out our cash runway substantially beyond where we are today," Berger said. "We're taking a fresh look at every component of our budget, every near- and long-term expenditure," he said, citing clinical trials, facilities and people.

Ariad plunged 41 percent to $2.67 at the close in New York yesterday, extending a record drop that started when the study enrollment was first halted earlier this month. The shares have lost 86 percent this year.

BMC gets two research awards

Boston Medical Center has been approved to receive two research awards from the Patient-Centered Outcomes Research Institute. One will fund a study of the delivery of cancer care to patients who face socio-legal barriers and the other a test of the effectiveness of integrative medical group visits for treating chronic pain.

THE SHUFFLE

• Thomas Hilditch, left, has been appointed a regional vice president of the 18,000-plus member Institute of Real Estate Management. His expertise includes site operations, staff development, budgeting, building systems, and community relations.
• Gary D. Hoffstein joins Needham-based Salus Capital Partners as the senior vice president, chief information officer, responsible for managing the direction of technology to support the firm's continued growth through strategic planning and evaluation.

Anda sedang membaca artikel tentang

The Ticker

Dengan url

http://bintanggugel.blogspot.com/2013/10/the-ticker_19.html

Anda boleh menyebar luaskannya atau mengcopy paste-nya

The Ticker

namun jangan lupa untuk meletakkan link

The Ticker

sebagai sumbernya